Cargando…

Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study

OBJECTIVE: To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture. Secondary objectives were to quantify functional outcome impairment and describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Samina, Gourlay, Katie, Yukseloglu, Aran, Rosychuk, Rhonda J, Ortiz, Silvia, Watts, Rick, Johnson, David W, Carleton, Bruce, Le May, Sylvie, Drendel, Amy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131055/
https://www.ncbi.nlm.nih.gov/pubmed/36053661
http://dx.doi.org/10.1136/bmjpo-2022-001428
_version_ 1784713104472408064
author Ali, Samina
Gourlay, Katie
Yukseloglu, Aran
Rosychuk, Rhonda J
Ortiz, Silvia
Watts, Rick
Johnson, David W
Carleton, Bruce
Le May, Sylvie
Drendel, Amy L
author_facet Ali, Samina
Gourlay, Katie
Yukseloglu, Aran
Rosychuk, Rhonda J
Ortiz, Silvia
Watts, Rick
Johnson, David W
Carleton, Bruce
Le May, Sylvie
Drendel, Amy L
author_sort Ali, Samina
collection PubMed
description OBJECTIVE: To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture. Secondary objectives were to quantify functional outcome impairment and describe demographic and clinical characteristics associated with AEs. DESIGN: Observational cohort study. SETTING: Paediatric emergency department. PATIENTS: Patients (n=240) aged 4–16 years diagnosed with an acute fracture. INTERVENTION: Prescribed either ibuprofen (n=179) or oxycodone (n=61) for pain. MAIN OUTCOME MEASURES: Families were called for the first 3 days after discharge to report the presence and intensity of AEs and their child’s functional outcomes (ability to eat, sleep, play or attend school). RESULTS: On day 1, children using oxycodone were more likely to report any AE (χ(2)(1)=13.5, p<0.001), nausea (χ(2)(1)=17.0, p<0.001), vomiting (χ(2)(1)=11.2, p<0.001), drowsiness (χ(2)(1)=13.7, p<0.001), constipation (χ(2)(1)=8.9, p=0.003) and dizziness (χ(2)(1)=19.1, p<0.001), compared with those using ibuprofen. Children receiving oxycodone reported greater severity of abdominal pain (oxycodone: mean 5.4 SD 3.1; ibuprofen mean 2.5 SD 1.4, F(1)(13)=6.5, p=0.02) on day 1 and worse intensity of constipation (oxycodone: mean 4.9 SD 2.1; ibuprofen mean 3.2 SD 2.2, F(1)(33)=4.5, p=0.04) over all 3 days. Use of oxycodone was associated with an increased odds of experiencing an AE on day 1 (OR=1.31 (95% CI 1.13 to 1.52)). Higher pain scores (OR=1.50 (95% CI 1.12 to 2.01)), lower extremity fracture (OR=1.25 (95% CI 1.07 to 1.47)) and undergoing ED sedation (OR=1.16 (95% CI 1.01 to 1.34)) were associated with missing school. Higher pain scores (OR=1.50 (95% CI 1.14 to 1.97)) and lower extremity fractures (OR=1.23 (95% CI 1.07 to 1.43)) were also associated with less play. CONCLUSIONS: Oxycodone is associated with more frequent AEs overall, higher intensity gastrointestinal AEs and greater functional limitations compared with ibuprofen. Lower extremity fractures cause more functional limitations than upper extremity fractures. Clinicians should consider these differences when providing fracture pain care for children.
format Online
Article
Text
id pubmed-9131055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91310552022-06-09 Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study Ali, Samina Gourlay, Katie Yukseloglu, Aran Rosychuk, Rhonda J Ortiz, Silvia Watts, Rick Johnson, David W Carleton, Bruce Le May, Sylvie Drendel, Amy L BMJ Paediatr Open Pain OBJECTIVE: To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture. Secondary objectives were to quantify functional outcome impairment and describe demographic and clinical characteristics associated with AEs. DESIGN: Observational cohort study. SETTING: Paediatric emergency department. PATIENTS: Patients (n=240) aged 4–16 years diagnosed with an acute fracture. INTERVENTION: Prescribed either ibuprofen (n=179) or oxycodone (n=61) for pain. MAIN OUTCOME MEASURES: Families were called for the first 3 days after discharge to report the presence and intensity of AEs and their child’s functional outcomes (ability to eat, sleep, play or attend school). RESULTS: On day 1, children using oxycodone were more likely to report any AE (χ(2)(1)=13.5, p<0.001), nausea (χ(2)(1)=17.0, p<0.001), vomiting (χ(2)(1)=11.2, p<0.001), drowsiness (χ(2)(1)=13.7, p<0.001), constipation (χ(2)(1)=8.9, p=0.003) and dizziness (χ(2)(1)=19.1, p<0.001), compared with those using ibuprofen. Children receiving oxycodone reported greater severity of abdominal pain (oxycodone: mean 5.4 SD 3.1; ibuprofen mean 2.5 SD 1.4, F(1)(13)=6.5, p=0.02) on day 1 and worse intensity of constipation (oxycodone: mean 4.9 SD 2.1; ibuprofen mean 3.2 SD 2.2, F(1)(33)=4.5, p=0.04) over all 3 days. Use of oxycodone was associated with an increased odds of experiencing an AE on day 1 (OR=1.31 (95% CI 1.13 to 1.52)). Higher pain scores (OR=1.50 (95% CI 1.12 to 2.01)), lower extremity fracture (OR=1.25 (95% CI 1.07 to 1.47)) and undergoing ED sedation (OR=1.16 (95% CI 1.01 to 1.34)) were associated with missing school. Higher pain scores (OR=1.50 (95% CI 1.14 to 1.97)) and lower extremity fractures (OR=1.23 (95% CI 1.07 to 1.43)) were also associated with less play. CONCLUSIONS: Oxycodone is associated with more frequent AEs overall, higher intensity gastrointestinal AEs and greater functional limitations compared with ibuprofen. Lower extremity fractures cause more functional limitations than upper extremity fractures. Clinicians should consider these differences when providing fracture pain care for children. BMJ Publishing Group 2022-05-23 /pmc/articles/PMC9131055/ /pubmed/36053661 http://dx.doi.org/10.1136/bmjpo-2022-001428 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Pain
Ali, Samina
Gourlay, Katie
Yukseloglu, Aran
Rosychuk, Rhonda J
Ortiz, Silvia
Watts, Rick
Johnson, David W
Carleton, Bruce
Le May, Sylvie
Drendel, Amy L
Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
title Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
title_full Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
title_fullStr Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
title_full_unstemmed Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
title_short Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
title_sort quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
topic Pain
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131055/
https://www.ncbi.nlm.nih.gov/pubmed/36053661
http://dx.doi.org/10.1136/bmjpo-2022-001428
work_keys_str_mv AT alisamina quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT gourlaykatie quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT yukselogluaran quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT rosychukrhondaj quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT ortizsilvia quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT wattsrick quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT johnsondavidw quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT carletonbruce quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT lemaysylvie quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy
AT drendelamyl quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy